Neurology · Pennsylvania
Neurology studies in Pennsylvania
99 studies have at least one recruiting site in Pennsylvania. Neurology research spans migraine, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, stroke and nerve pain.
99 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1/Phase 2Overnight stay mentioned
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Vector Y Therapeutics
- Location
- Philadelphia, PA + 3 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersEarly Phase 1
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
University of Pennsylvania
- Location
- Philadelphia, PA + 2 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingHealthy volunteersEarly Phase 1
Localizing Epileptic Networks Using MRI and iEEG
University of Pennsylvania
- Location
- Philadelphia, PA
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersEarly Phase 1
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
University of Pennsylvania
- Location
- Philadelphia, PA
- Eligibility basics
- Ages 40–80
- RecruitingHealthy volunteers
A Study to Evaluate the SENSE Device's Ability to Detect TBI
Sense Diagnostics, LLC
- Location
- Pittsburgh, PA + 5 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 2
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
Sanofi
- Location
- Plymouth Meeting, PA + 9 other US sites
- Eligibility basics
- Ages 55–85
- Recruiting
Diagnosing Epilepsy To EffeCT Change
Epiminder America, Inc.
- Location
- Philadelphia, PA + 21 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Rapport Therapeutics Inc.
- Location
- Philadelphia, PA + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Merck Sharp & Dohme LLC
- Location
- Plymouth Meeting, PA + 34 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Bethlehem, PA + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Abington, PA + 34 other US sites
- Eligibility basics
- Ages 55–95
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Hershey, PA + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Plymouth Meeting, PA + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
argenx
- Location
- Philadelphia, PA + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx
- Location
- Philadelphia, PA + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Media, PA + 57 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
phenox Inc.
- Location
- Philadelphia, PA + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Abington, PA + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
Epygenix
- Location
- Philadelphia, PA + 16 other US sites
- Eligibility basics
- Ages 2–55
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Philadelphia, PA + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Philadelphia, PA + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb
- Location
- Plymouth Meeting, PA + 22 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 2
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AllRock Bio, Inc.
- Location
- Philadelphia, PA + 10 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Philadelphia, PA + 25 other US sites
- Eligibility basics
- Ages 6–17
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Why do memory studies need a study partner?
A partner can report day-to-day changes the participant may not notice. Each study explains what the partner is asked to do.